Detalhe da pesquisa
1.
Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Annu Rev Pharmacol Toxicol
; 64: 455-479, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738504
2.
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Am J Hematol
; 99(2): E32-E36, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994196
3.
Functional genomic landscape of acute myeloid leukaemia.
Nature
; 562(7728): 526-531, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30333627
4.
Cytogenetically Cryptic Acute Promyelocytic Leukemia: A Diagnostic Challenge.
Int J Mol Sci
; 24(17)2023 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37685882
5.
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.
Clin Proteomics
; 19(1): 30, 2022 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35896960
6.
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
Blood
; 135(24): 2159-2170, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32315394
7.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
8.
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Proc Natl Acad Sci U S A
; 114(36): E7554-E7563, 2017 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28784769
9.
The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
Am J Hematol
; 94(8): 913-920, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31145495
10.
The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Am J Hematol
; 98(12): E364-E368, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815132
11.
Reducing acetyl-CoA enhances BET inhibition.
Blood
; 134(24): 2122-2123, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31830279
12.
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.
Blood
; 123(10): 1516-24, 2014 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24408322
13.
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Am J Hematol
; 96(7): E226-E229, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33780043
14.
Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.
Am J Hematol
; 91(2): 211-9, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26573090
15.
Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.
Cell Rep Med
; 5(1): 101359, 2024 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38232702
16.
Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia.
Cancers (Basel)
; 15(14)2023 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509251
17.
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
Blood Adv
; 7(9): 1899-1909, 2023 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36441905
18.
Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.
Br J Haematol
; 172(6): 983-6, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26095727
19.
IDH Inhibitors in AML-Promise and Pitfalls.
Curr Hematol Malig Rep
; 16(2): 207-217, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33939107
20.
Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse.
Transplant Cell Ther
; 27(8): 662.e1-662.e9, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33901720